Bosentan for scleroderma associated pulmonary arterial hypertension - A subgroup analysis of two placebo controlled trials.
CP Denton(The Royal Free Hospital), Casilda G. Black
UCL Discovery (University College London)
September 1, 2003
Cited by 1
Related Papers
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach
|Annals of the Rheumatic Diseases|2003|769
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial
|Annals of the Rheumatic Diseases|2010|503
Open-Label Trial of Anti-TNF-α in Dermato- and Polymyositis Treated Concomitantly with Methotrexate
|European Neurology|2008|99
Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test
|Annals of the Rheumatic Diseases|2006|98